Topiramate intervention to prevent transformation of episodic migraine

The topiramate INTREPID study

Richard B. Lipton, Stephen Silberstein, David Dodick, Roger Cady, Fred Freitag, Ninan Mathew, David M. Biondi, Steven Ascher, William H. Olson, Joseph Hulihan

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective: The study sought to evaluate whether topiramate prevents development of chronic daily headache (CDH, ≥15 headache days per month) in adult subjects with high-frequency episodic migraine (HFEM, 9-14 migraine headache days/ month). A secondary objective was to assess the efficacy of topiramate as preventive migraine treatment in this population. Methods: This was a multicenter, randomized, double-blind, placebo-controlled study comparing topiramate 100 mg/day and placebo for 26 weeks. The primary efficacy variable was new-onset CDH at month 6. Secondary efficacy measures included migraine and headache days. Adverse events (AEs) were evaluated. Results: A total of 159 topiramate subjects and 171 placebo subjects were efficacy-evaluable. At month 6, 1.4% of topiramate subjects versus 2.3% of placebo subjects had CDH (p =.589). Compared with placebo, topiramate treatment was associated with statistically significant reductions in mean number of migraine days (6.6 vs. 5.3/28 days; p =.001) and headache days (6.6 vs 5.3/28 days; p =.001). Most commonly reported AEs in the topiramate versus placebo group included paresthesia (32.4% vs. 7.0%), fatigue (14.8% vs. 8.6%), dizziness (11.4% vs. 7.6%) and nausea (10.8% vs. 9.2%). Conclusion: Topiramate 100 mg/day did not prevent the development of CDH at six months in subjects with HFEM. Topiramate was effective in reducing headache days and migraine headache days and generally well tolerated.

Original languageEnglish (US)
Pages (from-to)18-30
Number of pages13
JournalCephalalgia
Volume31
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Migraine Disorders
Placebos
Headache
topiramate
Headache Disorders
Paresthesia
Dizziness
Nausea
Fatigue
Therapeutics
Population

Keywords

  • chronic
  • migraine
  • preventive treatment
  • Topiramate
  • transformation

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Topiramate intervention to prevent transformation of episodic migraine : The topiramate INTREPID study. / Lipton, Richard B.; Silberstein, Stephen; Dodick, David; Cady, Roger; Freitag, Fred; Mathew, Ninan; Biondi, David M.; Ascher, Steven; Olson, William H.; Hulihan, Joseph.

In: Cephalalgia, Vol. 31, No. 1, 01.2011, p. 18-30.

Research output: Contribution to journalArticle

Lipton, RB, Silberstein, S, Dodick, D, Cady, R, Freitag, F, Mathew, N, Biondi, DM, Ascher, S, Olson, WH & Hulihan, J 2011, 'Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study', Cephalalgia, vol. 31, no. 1, pp. 18-30. https://doi.org/10.1177/0333102410372427
Lipton, Richard B. ; Silberstein, Stephen ; Dodick, David ; Cady, Roger ; Freitag, Fred ; Mathew, Ninan ; Biondi, David M. ; Ascher, Steven ; Olson, William H. ; Hulihan, Joseph. / Topiramate intervention to prevent transformation of episodic migraine : The topiramate INTREPID study. In: Cephalalgia. 2011 ; Vol. 31, No. 1. pp. 18-30.
@article{d161f3745a704c2dad3cf0ea36b9c9e2,
title = "Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study",
abstract = "Objective: The study sought to evaluate whether topiramate prevents development of chronic daily headache (CDH, ≥15 headache days per month) in adult subjects with high-frequency episodic migraine (HFEM, 9-14 migraine headache days/ month). A secondary objective was to assess the efficacy of topiramate as preventive migraine treatment in this population. Methods: This was a multicenter, randomized, double-blind, placebo-controlled study comparing topiramate 100 mg/day and placebo for 26 weeks. The primary efficacy variable was new-onset CDH at month 6. Secondary efficacy measures included migraine and headache days. Adverse events (AEs) were evaluated. Results: A total of 159 topiramate subjects and 171 placebo subjects were efficacy-evaluable. At month 6, 1.4{\%} of topiramate subjects versus 2.3{\%} of placebo subjects had CDH (p =.589). Compared with placebo, topiramate treatment was associated with statistically significant reductions in mean number of migraine days (6.6 vs. 5.3/28 days; p =.001) and headache days (6.6 vs 5.3/28 days; p =.001). Most commonly reported AEs in the topiramate versus placebo group included paresthesia (32.4{\%} vs. 7.0{\%}), fatigue (14.8{\%} vs. 8.6{\%}), dizziness (11.4{\%} vs. 7.6{\%}) and nausea (10.8{\%} vs. 9.2{\%}). Conclusion: Topiramate 100 mg/day did not prevent the development of CDH at six months in subjects with HFEM. Topiramate was effective in reducing headache days and migraine headache days and generally well tolerated.",
keywords = "chronic, migraine, preventive treatment, Topiramate, transformation",
author = "Lipton, {Richard B.} and Stephen Silberstein and David Dodick and Roger Cady and Fred Freitag and Ninan Mathew and Biondi, {David M.} and Steven Ascher and Olson, {William H.} and Joseph Hulihan",
year = "2011",
month = "1",
doi = "10.1177/0333102410372427",
language = "English (US)",
volume = "31",
pages = "18--30",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Topiramate intervention to prevent transformation of episodic migraine

T2 - The topiramate INTREPID study

AU - Lipton, Richard B.

AU - Silberstein, Stephen

AU - Dodick, David

AU - Cady, Roger

AU - Freitag, Fred

AU - Mathew, Ninan

AU - Biondi, David M.

AU - Ascher, Steven

AU - Olson, William H.

AU - Hulihan, Joseph

PY - 2011/1

Y1 - 2011/1

N2 - Objective: The study sought to evaluate whether topiramate prevents development of chronic daily headache (CDH, ≥15 headache days per month) in adult subjects with high-frequency episodic migraine (HFEM, 9-14 migraine headache days/ month). A secondary objective was to assess the efficacy of topiramate as preventive migraine treatment in this population. Methods: This was a multicenter, randomized, double-blind, placebo-controlled study comparing topiramate 100 mg/day and placebo for 26 weeks. The primary efficacy variable was new-onset CDH at month 6. Secondary efficacy measures included migraine and headache days. Adverse events (AEs) were evaluated. Results: A total of 159 topiramate subjects and 171 placebo subjects were efficacy-evaluable. At month 6, 1.4% of topiramate subjects versus 2.3% of placebo subjects had CDH (p =.589). Compared with placebo, topiramate treatment was associated with statistically significant reductions in mean number of migraine days (6.6 vs. 5.3/28 days; p =.001) and headache days (6.6 vs 5.3/28 days; p =.001). Most commonly reported AEs in the topiramate versus placebo group included paresthesia (32.4% vs. 7.0%), fatigue (14.8% vs. 8.6%), dizziness (11.4% vs. 7.6%) and nausea (10.8% vs. 9.2%). Conclusion: Topiramate 100 mg/day did not prevent the development of CDH at six months in subjects with HFEM. Topiramate was effective in reducing headache days and migraine headache days and generally well tolerated.

AB - Objective: The study sought to evaluate whether topiramate prevents development of chronic daily headache (CDH, ≥15 headache days per month) in adult subjects with high-frequency episodic migraine (HFEM, 9-14 migraine headache days/ month). A secondary objective was to assess the efficacy of topiramate as preventive migraine treatment in this population. Methods: This was a multicenter, randomized, double-blind, placebo-controlled study comparing topiramate 100 mg/day and placebo for 26 weeks. The primary efficacy variable was new-onset CDH at month 6. Secondary efficacy measures included migraine and headache days. Adverse events (AEs) were evaluated. Results: A total of 159 topiramate subjects and 171 placebo subjects were efficacy-evaluable. At month 6, 1.4% of topiramate subjects versus 2.3% of placebo subjects had CDH (p =.589). Compared with placebo, topiramate treatment was associated with statistically significant reductions in mean number of migraine days (6.6 vs. 5.3/28 days; p =.001) and headache days (6.6 vs 5.3/28 days; p =.001). Most commonly reported AEs in the topiramate versus placebo group included paresthesia (32.4% vs. 7.0%), fatigue (14.8% vs. 8.6%), dizziness (11.4% vs. 7.6%) and nausea (10.8% vs. 9.2%). Conclusion: Topiramate 100 mg/day did not prevent the development of CDH at six months in subjects with HFEM. Topiramate was effective in reducing headache days and migraine headache days and generally well tolerated.

KW - chronic

KW - migraine

KW - preventive treatment

KW - Topiramate

KW - transformation

UR - http://www.scopus.com/inward/record.url?scp=79751483735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79751483735&partnerID=8YFLogxK

U2 - 10.1177/0333102410372427

DO - 10.1177/0333102410372427

M3 - Article

VL - 31

SP - 18

EP - 30

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 1

ER -